Syntonix Pharmaceuticals, Boston startup biopharmaceutical company, was looking for additional funding for growth. The company has developed and patented an improved platform for the delivery of long-acting biological products, and then use the technology to develop a new therapy for the treatment of chronic diseases. Transceptor ® technology used unique biological pathways to allow efficient delivery SynFusion ™ drug therapy. Several companies licensed technologies in the development of joint proposals for various conditions: Hemophilia B, autoimmune diseases and infertility, as well as for use in the extended peptide inhalation. The company used the money and angel rounds and B venture financing and looking for an extra $ 80 - $ 100 million for growth. In September 2006, Syntonix was in negotiations with the VC syndicate to get the 'C' round of funding. One of the members of the proposed syndicate, Biogen Idec, expressed interest in buying Syntonix directly. The founders needed to make a decision on the proposal. "Hide
by Raymond M. Kinnunen, Susan F. Sieloff, Robert Young Source: North American Case Research Association (NACRA) 15 pages. Publication Date: January 25, 2009. Prod. #: NA0034-PDF-ENG
Related Case Solutions & Analyses:
Envia Systems
Franklin Health Associates (B)
Global Expansion at Sanford C. Bernstein (B) (Abridged)
The Export-Import Bank of the United States
Cleveland Clinic Heart Center: Legacy of Excellence
Wintel (F): From Multi-Geographic Contact to Open Source
Changing with the Times: South African Police in the Post-Apartheid Era (Sequel)
Bangkoks Second Stage Expressway
Does IP Strategy Have to Cripple Open Innovation?
Google- Project Oxygen
